Cargando…

Isolated splenic metastasis of endometrial cancer 12 years after treatment: A case report and literature review

RATIONALE: The spleen is an uncommon metastatic organ for malignant solid tumors because of its special anatomy and microenvironment. Isolated splenic metastasis of endometrial cancer is an extremely rare clinical event, with only 17 cases reported in literature. PATIENT CONCERNS: We report the case...

Descripción completa

Detalles Bibliográficos
Autores principales: Teng, Xiali, Jiang, Min, Zhu, Xiaowei, Dou, Rongrong, Yuan, Donglan, Huang, Junxing, Yu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276391/
https://www.ncbi.nlm.nih.gov/pubmed/35512074
http://dx.doi.org/10.1097/MD.0000000000029178
Descripción
Sumario:RATIONALE: The spleen is an uncommon metastatic organ for malignant solid tumors because of its special anatomy and microenvironment. Isolated splenic metastasis of endometrial cancer is an extremely rare clinical event, with only 17 cases reported in literature. PATIENT CONCERNS: We report the case of a 58-year-old woman with abdominal distension and nausea for 7 months who had undergone surgery and chemotherapy for endometrioid adenocarcinoma 12 years previously. A space-occupying lesion in the upper pole of the spleen was observed on an abdominal ultrasound. DIAGNOSIS: The spleen was resected, and splenic metastasis of endometrial adenocarcinoma was histologically confirmed. INTERVENTIONS: Splenectomy was performed, and no lymph nodes or other metastases were observed. The patient received postoperative chemotherapy with 6 cycles of docetaxel and carboplatin. OUTCOMES: The patient recovered well 11 months postoperatively, with no evidence of recurrence or metastatic disease. LESSON: Since the time interval between the diagnosis of primary endometrial cancer and splenic metastasis may be very long, it may be necessary to monitor the recurrence of endometrial cancer after primary treatment.